New Delhi: Serum Institute of India who produces the Covishield vaccine has sent it’s an application from India’s drug regulatory approval for Covishield as a booster dose citing adequate stock of the vaccine in the country and a demand for a booster shot due to the emergence of Omicron Variant.
SII has written the application to DGCI seeking a nod for approval. In the application, Prakash Kumar Singh, the Director, Government, and Regulatory Affairs at Serum Institute of India (SII) quoted that the UK’s Medicines and Healthcare products Regulatory Agency has already approved the booster dose of AstraZeneca ChAdOx1 nCoV-19 vaccine. The Covishield is actually the Astrazeneca Vaccine.
The application added, “You are aware that now there is no shortage of Covishield in our country and the demand for a booster dose is increasing day by day from the people who have already taken two doses in view of the ongoing COVID-19 pandemic and emergence of new strains. So, It is the need of the hour and a matter of right to health of every individual that they should be inoculated with third dose/booster dose to protect themselves in this pandemic situation.” Singh Asserted.
Along with this, Govt. of Kerala, Rajasthan, Karnataka, and Chhattisgarh have also requested the Centre to decide on allowing booster doses of COVID-19 vaccine diseased amid concerns raised by ‘Omicron’, the Omicron variant of SARS-CoV-2.